Pneumocystis Pneumonia Associated with Infliximab in Japan
- 1 November 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (18), 1874-1876
- https://doi.org/10.1056/nejmc070728
Abstract
Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is used in Japan for the treatment of patients with active rheumatoid arthritis that is resistant to methotrexate.1 Methotrexate is used only for patients who do not have a response to or cannot tolerate other disease-modifying antirheumatic drugs, such as sulfasalazine. Infliximab is not used as primary therapy for rheumatoid arthritis in Japan.Keywords
This publication has 5 references indexed in Scilit:
- Official Japanese guidelines for the use of infliximab for rheumatoid arthritisModern Rheumatology, 2005
- Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral TherapyNew England Journal of Medicine, 2001
- (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumoniaClinical and Diagnostic Laboratory Immunology, 1996
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988